cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.7680938
title: Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

description: Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes among the so-called poor-prognosis AML subsets, which generally refer to patients with adverse cytogenetic risk, secondary AML including therapy-related AML, poor-prognosis mutations, especially FLT3-ITD, and relapse/refractory AML. To the best of our knowledge, the role and efficacy of 7 + 3 schedules containing daunorubicin (DNR) and Ara-C for certain types of poor-prognosis AML has not been systematically assessed. A critical approach to the role of DNR and Ara-C induction could be relevant to establish which patients should be enrolled in clinical trials using novel therapies. In this regard, a recent randomized clinical trial (RCT) showed improved results in older patients with sAML or high-risk cytogenetics who received CPX-351 compared with standard 7 + 3 combination. We perform a systematic literature review to analyze the clinical outcomes reported with DNR plus Ara-C regimens in adult patients with poor-prognosis AML, the use of liposomal formulations of DNR and Ara-C and the RCTs which compared standard 7 + 3 with the addition of a third drug.
DOI: 10.6084/m9.figshare.14554362.v1
title: SourceData_ED3_d_CR.tsv.gz

description: Source Data ED3<br>
DOI: 10.6084/m9.figshare.11931711.v1
title: Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials

description: The link of acute pancreatitis (AP) with Incretin based therapies (IBTs) in type 2 diabetes has existed since United States Food and Drug Administration alert in 2010. This issue still remains unresolved due to conflicting results among studies. We performed a systematic search of the PubMed, Embase, and Cochrane Library databases until 31 July 2019, and retrieved all cardiovascular outcome trials (CVOTs) of IBTs conducted for ≥12 months that reported the pre-specified and or pre-adjudicated pancreatitis outcomes. Subsequently, we conducted a meta-analysis to study the risk of AP observed with IBT in CVOTs. A meta-analysis of seven CVOTs of GLP-1 receptor agonists (GLP-1RAs) compared with placebo (N = 55,932) found no significant increase in AP (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.77–1.42; p = 0.77). In contrast, meta-analysis of five CVOTs comparing DPP-4 inhibitors with placebo (N = 47,714) and six CVOTs comparing DPP-4 inhibitors with placebo or active comparator (N = 53,747), found a significant increase (OR, 1.81; 95% CI, 1.21–2.70; p = 0.04 and OR, 1.54; 95% CI, 1.08–2.18; p = 0.02, respectively) in AP without any significant heterogeneity. This meta-analysis revealed a significant association between pancreatitis and DPP-4 inhibitors; however, no such association was observed for GLP-1RAs.
DOI: 10.6084/m9.figshare.11931711
title: Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials

description: The link of acute pancreatitis (AP) with Incretin based therapies (IBTs) in type 2 diabetes has existed since United States Food and Drug Administration alert in 2010. This issue still remains unresolved due to conflicting results among studies. We performed a systematic search of the PubMed, Embase, and Cochrane Library databases until 31 July 2019, and retrieved all cardiovascular outcome trials (CVOTs) of IBTs conducted for ≥12 months that reported the pre-specified and or pre-adjudicated pancreatitis outcomes. Subsequently, we conducted a meta-analysis to study the risk of AP observed with IBT in CVOTs. A meta-analysis of seven CVOTs of GLP-1 receptor agonists (GLP-1RAs) compared with placebo (N = 55,932) found no significant increase in AP (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.77–1.42; p = 0.77). In contrast, meta-analysis of five CVOTs comparing DPP-4 inhibitors with placebo (N = 47,714) and six CVOTs comparing DPP-4 inhibitors with placebo or active comparator (N = 53,747), found a significant increase (OR, 1.81; 95% CI, 1.21–2.70; p = 0.04 and OR, 1.54; 95% CI, 1.08–2.18; p = 0.02, respectively) in AP without any significant heterogeneity. This meta-analysis revealed a significant association between pancreatitis and DPP-4 inhibitors; however, no such association was observed for GLP-1RAs.
DOI: 10.6084/m9.figshare.14554362
title: SourceData_ED3_d_CR.tsv.gz

description: Source Data ED3<br>
DOI: 10.5281/zenodo.4742276
title: Perceived value interviews and socio-economic survey data in seven villages in rural Uganda

description: Dataset (JSON and CSV files) of 119 interviews conducted between 2014 and 2015 in seven rural Ugandan villages from surveys and face-to-face interviews.
DOI: 10.25345/c5w522
title: MassIVE MSV000087381 - Comprehensive characterization of the embryonic factor LEUTX
title: Affinity purification and BioID Mass spectrometry files for LEUTX and two mutants (LEUTX_K57A, LEUTX_9aaTADdel)
DOI: 10.6084/m9.figshare.14554431
title: SourceData_Fig3.xlsx

description: Source Data Fig.3<br>
DOI: 10.6084/m9.figshare.14554431.v1
title: SourceData_Fig3.xlsx

description: Source Data Fig.3<br>
DOI: 10.5281/zenodo.4742284
title: Monolayer-WxVyOz/TiO2-structures for selective catalytic reduction study

description: Optimized monolayer-W~x~V~y~O~z~/TiO~2~ structures Software: vasp
DOI: 10.5281/zenodo.4742283
title: Monolayer-WxVyOz/TiO2-structures for selective catalytic reduction study

description: Optimized monolayer-W~x~V~y~O~z~/TiO~2~ structures Software: vasp
DOI: 10.48370/ofd/btidn9
title: Linospora saligna (Ehrh. Ex Pers.) Traverso, 773

description: Fungarium Mikromycetes
DOI: 10.6084/m9.figshare.14211875.v2
title: Chinese herbal medicine for the treatment of children and adolescents with Refractory Mycoplasma Pneumoniae Pneumonia: a systematic review and a meta-analysis

description: Table S1 Search strategy 2Table S2 Characteristics of adverse events for included studies 5Table S3 Supplement Details respecting to the information of Self-made formulas 8Table S4 Supplement Details respecting to the information of Chinese patent medicines 11File 1 PRISMA checklist. 14File 2 A list of excluded studies by reading full text 17FigureS1 Sensitivity analysis 20
DOI: 10.6084/m9.figshare.14211875
title: Chinese herbal medicine for the treatment of children and adolescents with Refractory Mycoplasma Pneumoniae Pneumonia: a systematic review and a meta-analysis

description: Table S1 Search strategy 2Table S2 Characteristics of adverse events for included studies 5Table S3 Supplement Details respecting to the information of Self-made formulas 8Table S4 Supplement Details respecting to the information of Chinese patent medicines 11File 1 PRISMA checklist. 14File 2 A list of excluded studies by reading full text 17FigureS1 Sensitivity analysis 20
DOI: 10.6084/m9.figshare.14211875.v1
title: Untitled Item

description: <b>附表</b><b>1</b> 纳入研究 的中药成分和制剂质量控制。 <b></b>
DOI: 10.5281/zenodo.4742001
title: All's well that ends well: an early-phase study testing lower end-session exercise intensity to promote physical activity in patients with Parkinson's disease

description: This dataset includes: 1) materials (in French) 2) workbook 3) self-reported data (i.e., questionnaires) - "data_selfreport_zen.csv" & "data_SRPA_zen.csv" 4) E-prime data (i.e., Implicit association test) - "data_IAT_zen.csv" 5) accelerometer-based data - "data_accePA_zen.csv"
DOI: 10.5517/cctmhhd
title: CCDC 763514: Experimental Crystal Structure Determination

description: Related Article: J.Chu, Z.Y.Liu, X.J.Zhao, E.C.Yang|2010|Koord.Khim.|36|913|
DOI: 10.5517/ccdc.csd.cc23z2pw
title: CCDC 1965328: Experimental Crystal Structure Determination

description: Related Article: Junhao Wang,  Jakub J. Zakrzewski,  Michal Heczko,  Mikolaj Zychowicz,  Kosuke Nakagawa,  Koji Nakabayashi,  Barbara Sieklucka,  Szymon Chorazy,  Shin-ichi Ohkoshi|2020|J.Am.Chem.Soc.|142|3970|doi:10.1021/jacs.9b13147
DOI: 10.5517/ccdc.csd.cc25p197
title: CCDC 2016218: Experimental Crystal Structure Determination

description: Related Article: Miao Wang, Hong−Juan Xu, Tong−Ming Sun, Hui−Hui Cui, Yi-Quan Zhang, Lei Chen, Yan−Feng Tang|2021|J.Solid State Chem.|299|122209|doi:10.1016/j.jssc.2021.122209
DOI: 10.5517/ccdc.csd.cc2714xc
title: CCDC 2056692: Experimental Crystal Structure Determination

description: Related Article: Jing Yuan Zhang, XiuLi Wang, ZhiHan Chang, Zhong Zhang, Xiang Wang, HongYan Lin|2021|Inorg.Chem.Commun.|129|108580|doi:10.1016/j.inoche.2021.108580
DOI: 10.6084/m9.figshare.8256899.v2
title: An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

description: <b>Introduction</b>: Innate immune response and bone remodeling are key factors contributing to the pathogenesis of psoriatic arthritis (PsA). Moreover, the evidence of autoantibodies in patients’ sera suggests an autoimmune side in PsA. Besides the immune pathways, studies strongly support the role of genetic risk alleles in affecting the clinical heterogeneity of PsA as well as the response to therapy. A good clinical response to treatment, indeed, represents a challenge in PsA patients and the identification of patient-targeted therapies is still a critical issue. <b>Areas covered</b>: We performed a systematic review aiming at describing new evidence on PsA pathogenesis and treatments. Reported items for systematic reviews (PRISMA checklist) were analyzed. Studies included from the PubMed database addressed the following items: innate immunity, autoimmunity, bone remodeling, and therapeutic targets in PsA; time frame of research 1970–2019. Specifically, we reviewed data on IL-17 inhibitors, abatacept, JAK inhibitors, ABT 122, and A (3) adenosine receptors agonist, CF101. <b>Expert opinion</b>: In PsA an intriguing pathogenetic network has been documented. Several biological and synthetic drugs are promising in terms of efficacy and safety profile.
DOI: 10.5517/ccdc.csd.cc2714yd
title: CCDC 2056693: Experimental Crystal Structure Determination

description: Related Article: Jing Yuan Zhang, XiuLi Wang, ZhiHan Chang, Zhong Zhang, Xiang Wang, HongYan Lin|2021|Inorg.Chem.Commun.|129|108580|doi:10.1016/j.inoche.2021.108580
DOI: 10.6084/m9.figshare.8256899
title: An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

description: <b>Introduction</b>: Innate immune response and bone remodeling are key factors contributing to the pathogenesis of psoriatic arthritis (PsA). Moreover, the evidence of autoantibodies in patients’ sera suggests an autoimmune side in PsA. Besides the immune pathways, studies strongly support the role of genetic risk alleles in affecting the clinical heterogeneity of PsA as well as the response to therapy. A good clinical response to treatment, indeed, represents a challenge in PsA patients and the identification of patient-targeted therapies is still a critical issue. <b>Areas covered</b>: We performed a systematic review aiming at describing new evidence on PsA pathogenesis and treatments. Reported items for systematic reviews (PRISMA checklist) were analyzed. Studies included from the PubMed database addressed the following items: innate immunity, autoimmunity, bone remodeling, and therapeutic targets in PsA; time frame of research 1970–2019. Specifically, we reviewed data on IL-17 inhibitors, abatacept, JAK inhibitors, ABT 122, and A (3) adenosine receptors agonist, CF101. <b>Expert opinion</b>: In PsA an intriguing pathogenetic network has been documented. Several biological and synthetic drugs are promising in terms of efficacy and safety profile.
DOI: 10.6084/m9.figshare.13048030.v1
title: Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis

description: To synthetize the available evidence concerning efficacy and safety of imatinib mesylate, a tyrosine kinase inhibitor, in systemic sclerosis (SSc). A systematic search following the PRISMA-statement in PubMed/MEDLINE, Cochrane CENTRAL, and Web of Science databases up to 7 February 2020 was conducted. Considering the substantial heterogeneity expected, a random-effects model to pool data from selected studies was adopted. After a treatment period ranging from 6 to 12 months, the pooled analysis revealed that imatinib mesylate significantly improved modified Rodnan skin score (mRSS) (mean difference [MD] = −3.091, 95%CI −6.081 to −0.102, p = 0.043), whereas health-related assessment questionnaire (HAQ) remains unchanged (−0.096; 95 CI −0.197 to −0.006). Data regarding change in pulmonary function tests were insufficiently consistent to be considered eligible for meta-analysis. Finally, regarding safety, the authors found a pooled dropout rate due to all adverse events of 22% and a rate of serious adverse events of 17%. The significant change within the range of clinical relevance of mRSS suggests the possible use of imatinib mesylate in SSc, whereas it is still not possible to draw firm conclusions regarding the efficacy of the drug on lung involvement. Specifically designed and powered studies are needed to investigate imatinib mesylate therapy in SSc.
DOI: 10.6084/m9.figshare.13048030
title: Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis

description: To synthetize the available evidence concerning efficacy and safety of imatinib mesylate, a tyrosine kinase inhibitor, in systemic sclerosis (SSc). A systematic search following the PRISMA-statement in PubMed/MEDLINE, Cochrane CENTRAL, and Web of Science databases up to 7 February 2020 was conducted. Considering the substantial heterogeneity expected, a random-effects model to pool data from selected studies was adopted. After a treatment period ranging from 6 to 12 months, the pooled analysis revealed that imatinib mesylate significantly improved modified Rodnan skin score (mRSS) (mean difference [MD] = −3.091, 95%CI −6.081 to −0.102, p = 0.043), whereas health-related assessment questionnaire (HAQ) remains unchanged (−0.096; 95 CI −0.197 to −0.006). Data regarding change in pulmonary function tests were insufficiently consistent to be considered eligible for meta-analysis. Finally, regarding safety, the authors found a pooled dropout rate due to all adverse events of 22% and a rate of serious adverse events of 17%. The significant change within the range of clinical relevance of mRSS suggests the possible use of imatinib mesylate in SSc, whereas it is still not possible to draw firm conclusions regarding the efficacy of the drug on lung involvement. Specifically designed and powered studies are needed to investigate imatinib mesylate therapy in SSc.
DOI: 10.6084/m9.figshare.8256899.v1
title: An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

description: <b>Introduction</b>: Innate immune response and bone remodeling are key factors contributing to the pathogenesis of psoriatic arthritis (PsA). Moreover, the evidence of autoantibodies in patients’ sera suggests an autoimmune side in PsA. Besides the immune pathways, studies strongly support the role of genetic risk alleles in affecting the clinical heterogeneity of PsA as well as the response to therapy. A good clinical response to treatment, indeed, represents a challenge in PsA patients and the identification of patient-targeted therapies is still a critical issue. <b>Areas covered</b>: We performed a systematic review aiming at describing new evidence on PsA pathogenesis and treatments. Reported items for systematic reviews (PRISMA checklist) were analyzed. Studies included from the PubMed database addressed the following items: innate immunity, autoimmunity, bone remodeling, and therapeutic targets in PsA; time frame of research 1970–2019. Specifically, we reviewed data on IL-17 inhibitors, abatacept, JAK inhibitors, ABT 122, and A (3) adenosine receptors agonist, CF101. <b>Expert opinion</b>: In PsA an intriguing pathogenetic network has been documented. Several biological and synthetic drugs are promising in terms of efficacy and safety profile.
DOI: 10.5517/ccdc.csd.cc273xy7
title: CCDC 2059359: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Michael Tüchler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273xz8
title: CCDC 2059360: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Natascha Stock, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273y1c
title: CCDC 2059362: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Michael Tüchler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273y4g
title: CCDC 2059365: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Sebastian Rücker, Jörg A. Schachner, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.6084/m9.figshare.12850394
title: Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency

description: Secondary immunodeficiency is becoming a greater medical concern as the usage of immunosuppressive and biological treatments has increased. Individuals with certain medical conditions, such as hematological malignancies, can also have secondary immunodeficiency. Immunoglobulin replacement therapy (IGRT), which has been used for decades in inherited or primary immunodeficiency, provides some protection to patients with acquired and predominant antibody deficiency, i.e. secondary antibody deficiency (SAD). However, IGRT is costly, and supplies are limited. Although there are clinical guidelines on when to initiate IGRT, there is no guideline on when to discontinue it. The authors reviewed existing literature and provided an overview of the current state of knowledge regarding IGRT discontinuation in SAD patients. Long-term supplementary immunoglobulin may not be necessary. Although it is possible to successfully transition away from IGRT in individuals with SAD, evidence-based practices are limited. Without clear guidelines and reliable prognostic markers, IGRT discontinuation practices are restricted to clinical judgment. For this reason, additional research should be conducted to identify markers that indicate the recovery of humoral immunity. Furthermore, the derivation and validation of a set of combined clinical and laboratory criteria to allow safe and timely IGRT discontinuation is warranted.
DOI: 10.5517/ccdc.csd.cc273y5h
title: CCDC 2059366: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Stefan Holler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.6084/m9.figshare.12850394.v1
title: Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency

description: Secondary immunodeficiency is becoming a greater medical concern as the usage of immunosuppressive and biological treatments has increased. Individuals with certain medical conditions, such as hematological malignancies, can also have secondary immunodeficiency. Immunoglobulin replacement therapy (IGRT), which has been used for decades in inherited or primary immunodeficiency, provides some protection to patients with acquired and predominant antibody deficiency, i.e. secondary antibody deficiency (SAD). However, IGRT is costly, and supplies are limited. Although there are clinical guidelines on when to initiate IGRT, there is no guideline on when to discontinue it. The authors reviewed existing literature and provided an overview of the current state of knowledge regarding IGRT discontinuation in SAD patients. Long-term supplementary immunoglobulin may not be necessary. Although it is possible to successfully transition away from IGRT in individuals with SAD, evidence-based practices are limited. Without clear guidelines and reliable prognostic markers, IGRT discontinuation practices are restricted to clinical judgment. For this reason, additional research should be conducted to identify markers that indicate the recovery of humoral immunity. Furthermore, the derivation and validation of a set of combined clinical and laboratory criteria to allow safe and timely IGRT discontinuation is warranted.
DOI: 10.5517/ccdc.csd.cc273y6j
title: CCDC 2059367: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Stefan Holler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yht
title: CCDC 2059376: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Natascha Stock, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yjv
title: CCDC 2059377: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Michael Tüchler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273ylx
title: CCDC 2059379: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yq1
title: CCDC 2059383: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273ys3
title: CCDC 2059385: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yt4
title: CCDC 2059386: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yv5
title: CCDC 2059387: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Jörg A. Schachner, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yx7
title: CCDC 2059389: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273yy8
title: CCDC 2059390: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Jörg A. Schachner, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2741bs
title: CCDC 2059464: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Stefan Holler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2743q7
title: CCDC 2059538: Experimental Crystal Structure Determination

description: Related Article: yusheng zhou|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc274gpk
title: CCDC 2059878: Experimental Crystal Structure Determination

description: Related Article: Mark Bartolo, Stephen Tsui, Pierre LeMagueres, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc274h52
title: CCDC 2059893: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Niklas Zwettler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc274h63
title: CCDC 2059894: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Lydia M. Peschel, Jörg A. Schachner, Nadia C. Mösch-Zanetti|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc274h74
title: CCDC 2059895: Experimental Crystal Structure Determination

description: Related Article: Ferdinand Belaj, Michael Tüchler, Nadia C. Mösch-Zanetti|2021|CSD Communication|||